Clinical Trials Directory

Trials / Completed

CompletedNCT00638521

Immune-cell Membrane Trafficking

Trauma and Sepsis Induced Changes in Immune-cell Membrane Receptor Trafficking

Status
Completed
Phase
Study type
Observational
Enrollment
213 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Organ failure following trauma is a leading cause of morbidity and mortality. It appears that the development of organ failure is a direct result of an altered immune response. This altered response results in the production of circulating factors in the blood that causes direct injury to the injured patients' organs. The mechanism in which this altered immune response occurs is unknown. Based on work we have performed in our laboratory, we believe that this response is initiated on the cell membrane of particular immune cells known as macrophages. Although the cell membrane may appear uniform, it is not. The membrane is composed of specific segments that allow proteins to associate with each other forming receptors that are required for immune cell activation. These specific membrane components are composed of various lipids and cholesterol, and have been termed lipid rafts. Based on our laboratory work it appears that these lipid rafts can be altered following injury. In particular both the lipid and protein content within these raft segments may be altered allowing immune cells to become active leading to the production of factors that directly injure normal cells and organs. Thus, we plan to examine if these laboratory findings can be seen in patients suffering from trauma who develop clinical organ failure at Harborview Medical Center. If this is accomplished, this data will lead to the development of both prognostic and therapeutic interventions for the optimal care of injured patient

Conditions

Timeline

Start date
2008-06-01
Primary completion
2012-08-01
Completion
2013-06-01
First posted
2008-03-19
Last updated
2013-12-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00638521. Inclusion in this directory is not an endorsement.